Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is one among the common adverse drug reactions and the leading causes of drug development attritions, black box warnings, and post-marketing withdrawals. Despite having relatively low clinical incidence, its potentially severe adverse events should be considered in the individual patients due to the high risk of acute liver failure. Although traditional liver parameters have been applied to the diagnosis of DILI, the lack of specific and sensitive biomarkers poses a major limitation, and thus accurate prediction of the subsequent clinical course remains a significant challenge. These drawbacks prompt the investigation and discovery of more effective biomarkers, which could lead to early detection of DILI, and improve its diagnosis and prognosis. Novel promising biomarkers include glutamate dehydrogenase, keratin 18, sorbitol dehydrogenase, glutathione S-transferase, bile acids, cytochrome P450, osteopontin, high mobility group box-1 protein, fatty acid binding protein 1, cadherin 5, miR-122, genetic testing, and omics technologies, among others. Furthermore, several clinical scoring systems have gradually emerged for the diagnosis of DILI including the Roussel Uclaf Causality Assessment Method (RUCAM), Clinical Diagnostic Scale (CDS), and Digestive Disease Week Japan (DDW-J) systems. However, currently their predictive value is limited with certain inherent deficiencies. Thus, perhaps the greatest benefit would be achieved by simultaneously combining the scoring systems and those biomarkers. Herein, we summarized the recent research progress on molecular biomarkers for DILI to improved approaches for its diagnosis and clinical management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.96 · Cited by 2,421
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Circulating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652 · cited 3×
“It becomes released into the extracellular space following cellular damage (Rovere-Querini et al., 2004; Huebener et al., 2015).”
BackgroundIncidence and Etiology of Drug-Induced Liver Injury in Mainland China
Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P. B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.002 · Cited by 615
Self-citationGenome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1
de Boer, Y. S., van Gerven, N. M. F., Zwiers, A., Verwer, B. J., van Hoek, B., van Erpecum, K. J., Beuers, U., van Buuren, H. R., Drenth, J. P. H., den Ouden, J. W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.022 · Cited by 304
Antoine, D. J., Williams, D. P., Kipar, A., Jenkins, R. E., Regan, S. L., Sathish, J. G., Kitteringham, N. R., & Park, B. K. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp235 · Cited by 223
Cited by
Bodaghi, A., Fattahi, N., & Ramazani, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13323 · Cited by 336
RetractedA critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Mechanism of Idiosyncratic Drug Induced Liver Injury (DILI): Unresolved Basic Issues
Teschke, R., & Uetrecht, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-2020-ubih-05 · Cited by 58
The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
Moreno-Torres, M., Quintás, G., & Castell, J. V. (2022) · Metabolites · doi:10.3390/metabo12060564 · Cited by 50
Ravindra, K. C., Vaidya, V. S., Wang, Z., Federspiel, J. D., Virgen-Slane, R., Everley, R. A., Grove, J. I., Stephens, C., Ocana, M. F., Robles-Díaz, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36858-6 · Cited by 44
Metadata
- Authors
- Fu, S., Wu, D., Jiang, W., Li, J., Long, J., Jia, C., & Zhou, T.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-01-30
- Volume
- 10
- Pages
- 1667-1667
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3004094806
- Cited by
- 137
- References
- 10
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives. https://app.cochat.ai/papers/10.3389/fphar.2019.01667
- The paper
- Fu, S., Wu, D., Jiang, W., Li, J., Long, J., Jia, C., & Zhou, T. (2020). Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2019.01667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.